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Extremes of body temperature occur in about half of patients in the operating room or in the critical care unit, contributing to morbidity and mortality.1–3 
These alterations in temperature can result in fluctuations 
between hypothermia or hyperthermia, which may result 
from a wide range of clinical complications.4 Although 
hypothermia is associated with hypocoagulable states, 
hyperthermia can result in a hypercoagulable state.5–10 
These effects of temperature on coagulation can be dem-
onstrated as abnormalities in the organization of the fibrin 
network that determines the microstructure of the clot.11–16 
Clots formed under hypercoagulable conditions will have 
more tightly packed fibrin networks, which are more resis-
tant to deformation and breakdown compared with clots 
formed under hypocoagulable conditions.14–16
Previous studies have attempted to investigate the effects 
of temperature change on coagulation by using a variety of 
viscoelastic techniques, including thromboelastography 
(Haemoscope Inc., Niles, IL), rotational thromboelastom-
etry (Tem International Gmbh, Munich, Germany), and free 
oscillation rheometry.17–23 There is some evidence to suggest 
that hyperthermia causes a procoagulant effect.9 Although 
hypothermia is known to reduce the rate of clot forma-
tion, the effect of temperature on maximum clot strength is 
unclear, with some studies showing little or no change and 
others reporting significant changes from 33°C to 28°C.23–26
Recent advances in studying viscoelastic changes in 
coagulation have led to the development of a novel rheo-
logical test for the analysis of clotting characteristics, includ-
ing an assessment of clot microstructure.14–16,27 In contrast 
to standard coagulation assays, this technique uses whole 
blood, and it accurately measures coagulation based on the 
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attainment of a gel point.14–16 The gel point identifies the 
transition of the blood from a viscoelastic liquid to a vis-
coelastic solid state, which signifies the first point at which 
the clot forms an unbroken structure. Taking rheological 
measurements at the gel point provides 3 important and 
related measurements: the elastic modulus at the gel point, 
G′GP, which is a measure of clot elasticity; the time to the gel 
point, TGP, which is a measure of how long it takes to form 
the clot; and the fractal dimension of the clot at the gel point, 
df, which quantifies the microstructure of the clot. In previ-
ous in vitro studies of hemodilution and anticoagulation, 
we have shown that the measurement of the gel point pro-
vides better prediction of coagulation abnormalities than 
conventional markers.14,16
The aim of this preclinical in vitro study is to determine 
whether temperature change over a range of 27°C to 43°C 
will cause alterations in the microstructural properties of 
the clot. We hypothesize that because temperatures are 
reduced to the mild and severe hypothermic range, signifi-
cant changes in the gel point parameters will occur, where 
the clot will form more slowly and produce reductions in df. 
We also hypothesize that increases of temperature into the 
hyperthermic range will also cause a significant change in 
the gel point parameters, where we will see quicker-form-
ing clots with increases in df.
Methods
The study was approved by the Wales Research Ethics 
Committee 6. Informed written consent was obtained from 
all subjects before enrolment. The exclusion criteria were 
as follows: (1) individuals with acute or chronic conditions 
known to effect coagulation (i.e., malignancy, hepatic, and/
or renal dysfunction); (2) individuals undergoing antiplate-
let or anticoagulation treatment; (3) individuals with a fam-
ily history of bleeding or thromboembolic disorders; and (4) 
anyone younger than 18 years.
Blood sampling
Before blood sampling, each healthy volunteer was 
assigned to 1 in vitro test temperature, ranging from 27°C 
to 43°C increasing in 1°C increments (n = 8 for each temper-
ature). Blood samples were obtained from the antecubital 
vein through an 18-gauge needle. The first 2 mL of blood 
was discarded after which 20 mL of blood was collected in 
a plastic syringe. The blood sample was then immediately 
divided into 2 aliquots. The first whole-blood aliquot was 
transferred to the AR-G2 (TA Instruments, New Castle, 
DE) rheometer for testing. The second sample was used for 
subsequent standard coagulation screening and full blood 
counts to ensure that each volunteer had a normal coagula-
tion profile.
Gel Point Measurements
The gel point technique has been validated previously.14 In 
this study, 6.6 mL of whole nonanticoagulated venous blood 
was placed into a double-gap concentric cylinder geometry 
testing surface mounted on a AR-G2−controlled stress rhe-
ometer. Immediately after sample loading, small amplitude 
oscillatory shear measurements were performed at test fre-
quencies 2, 0.93, 0.43, and 0.2 Hz to obtain measurements 
of the viscoelastic properties of coagulating blood, and the 
formation of the gel point was recorded. Identification of 
the gel point was then used to find (1) the time taken to 
reach the gel point, TGP; (2) the shear elastic modulus at the 
gel point, G′GP; and (3) the fractal dimension of the clot, df. 
A more detailed description of the gel point technique can 
be found in the Supplemental Digital Content (http://links.
lww.com/AA/B244).
Close temperature control was achieved through an inte-
grated Peltier concentric cylinder system (valid between 
−10°C and 150°C and is accurate within 0.1°C). The temper-
atures were checked using a thermocouple (P.I.8013, Portec 
type K thermometer, Wrestlingworth, United Kingdom). 
The process was repeated for all temperatures studied. The 
time taken for whole blood to reach the test temperatures 
after being loaded onto the testing surface (within 0.2°C) 
never exceeded 10 seconds.
Computational simulation
In conjunction with the gel point measurements, we also 
provide a previously published computational simulation.28 
This simulation was used alongside the experimental data 
collected from the gel point measurements to help illustrate 
how any changes in incipient clot microstructure (df) will 
relate to changes in the mass of the clot. This computational 
simulation will use the established relationship between 
incipient fibrin clots and their fractal properties, where the 
mass, M, is related to df by the following power law equa-
tion: M ≈ ɛdf, where ɛ is a length scale value in the range 100 
nm to 10 μm.29
standard Coagulation Markers
The second aliquot of blood (4.5 mL of the remaining blood) 
was immediately transferred to a siliconized glass Vacutainer 
(Becton-Dickinson, Plymouth, United Kingdom; Ref: 367691) 
for routine coagulation studies, including prothrombin time, 
activated partial thromboplastin time, and fibrinogen con-
centration measured using the method of Clauss.30 These 
were measured with a Sysmex CA1500 analyzer (Sysmex Co., 
Milton Keynes, UK) within 2 hours of collection. Fibrinogen 
concentration was verified against the second International 
Fibrinogen Standard version 4 (NIBSC code: 96–612; NIBSC, 
Hertfordshire, UK). All reagents were obtained from Siemens 
(Frimley, UK). The analyzer was calibrated according to the 
manufacturer’s instructions.
statistical Analysis
Statistical analysis was performed using Minitab® version 
16 software (Minitab Inc., Havertown, PA) and GraphPad 
Prism® version 6.0 (GraphPad Software Inc., La Jolla, CA). 
To establish at what temperature significant changes in df 
would occur compared with the value at 37°C, the number 
of participants per temperature was calculated by a power 
calculation. The sample size of this study was based on the 
previous studies, where the df at 37°C was 1.73 ± 0.035,13 
and expecting a decrease in df of approximately 0.06 as 
temperature is decreased into the moderate or severe 
hypothermic range (below 33°C). Assuming an α of 0.05 
and a power of 0.90, we calculated that 8 subjects would 
be required for each studied temperature, with a total of 17 
Copyright © 2015 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.Copyright © 2015 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
January 2016 • Volume 122 • Number 1 www.anesthesia-analgesia.org  23
  
different temperature graduations (ranging from 27°C to 
43°C in 1°C intervals) giving a total of 136 participants. We 
used the Anderson-Darling method and inspection of the 
distribution of the residuals to ascertain that TGP, G′GP, and 
df were normally distributed. One-way analysis of variance 
was performed to allow for a Bonferroni-corrected multiple 
comparisons test to be performed post hoc, which was used 
(for all 17 different groups) to determine the exact tempera-
tures when true differences arose from the values at 37°C. 
Pearson correlation was used to explore associations among 
temperature, df, TGP, and G′GP.
Results
The standard coagulation measurements for all 136 volun-
teers are reported in Table 1. These results confirmed that 
all subjects had normal coagulation. At 37°C, the values of 
df (mean ± SD, 1.73 ± 0.039) and TGP (mean ± SD, 231 ± 55) 
were similar to the values of those reported for healthy vol-
unteers measured in 2 previous studies.11,14,16 Figure 1 shows 
that increasing or decreasing temperature > or <37°C results 
in incremental changes in the gel point measurements. 
Progressive increases in temperature from 27°C to 43°C 
resulted in a progressive increase in both df and G′GP, show-
ing significant positive correlations with temperature (df: r = 
0.777, P < 0.0005; G′GP: r = 0.513, P = 0.0008). TGP decreased 
as temperature increased (r = −0.641, P < 0.0005). Moreover, 
df decreased from (mean ± SD) 1.73 ± 0.039 at 37°C to 1.64 
± 0.039 at 27°C with the change becoming significant at 
32°C (df = 1.67 ± 0.037; Bonferroni-corrected P = 0.0093; 95% 
confidence interval of the difference, 0.010–0.120). A signifi-
cant decrease in TGP occurs at <29°C (Bonferroni-corrected 
P = 0.0317; 95% confidence interval of the difference, −285 
to −7). By comparison no significant change was observed 
for G′GP as temperature decreased from 37°C (Bonferroni-
corrected P > 0.75 for all the different temperature groups 
in this range). Correlations were found between TGP and df 
(r = −0.562, P < 0.0005) and between df and G′GP (r = 0.719, 
P < 0.0005).
The computational simulation results (Fig. 2A) showed 
that as df decreases with corresponding decreases in tem-
perature (specifically ≤32°C), large decreases in clot mass 
are observed. Figure 2B shows that a df of 1.65 (correspond-
ing to a temperature of 28°C) would produce a clot that 
contains approximately 40% the mass from a clot formed 
with a df of 1.73 (37°C; see Fig. 2C). Figure 2A shows that 
the small incremental increases in df would require expo-
nential increases in mass. Figure 2D shows that a df of 1.80 
(some of the highest single values observed) would require 
a structure with 120% additional mass compared with one 
formed at a df of 1.73.
disCussion
In this study, we observed significant changes in the gel 
point measurements when temperatures fell into the hypo-
thermic range but not when they increased into the hyper-
thermic range. Furthermore, we found that the structural 
organization of the clot (df) is related to the kinetics of clot 
formation (TGP) and its elastic properties (G′GP) documented 
as significant correlations found between df and TGP and df 
and G′GP.
Hypothermia is common in critical illness, trauma, and 
during surgery, and it has been linked with excessive bleed-
ing, blood transfusion, and poor outcomes.1,3,31 Previous in 
Table 1.  The Normal Coagulation Profile of 
the Study Participants with Normal Ranges for 
Reference
Coagulation profile Result Normal range
PT (s) 10.4 ± 0.4 9–12.5
aPTT (s) 25.7 ± 1.9 22.1–30.9
Fibrinogen Clauss (g/L) 2.9 ± 0.5 1.5–4.2
Hemoglobin (g/L) 149 ± 15 130–180
Platelets (× 109/L) 263 ± 58 150–400
Hematocrit (vol/vol) 0.441 ± 0.039 0.40–0.52
PT = prothrombin time; aPTT = activated partial thromboplastin time.
Figure 1. Graphs of the changes in (A) fractal dimension (df), 
(B) time to the gel point (TGP), and (C) elastic modulus (G′GP) with 
progressive alterations in temperature. A, At lower temperatures, a 
reduced value of df is observed, which represents a poorly formed, 
weak, porous clot. The reverse is seen at high temperatures, with a 
stronger, more densely formed clot produced. B, As temperature is 
decreased a prolongation in  TGP is observed indicating a hypocoagu-
lable effect. C, A progressive increase in G′GP is observed as temper-
ature is increased, indicating a general increase in clot strength at 
higher temperatures (P < 0.05, 1-way analysis of variance Bonferroni 
multiple comparisons test). Dotted lines represent the mean and 
SD at 37°C.
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vitro studies have shown that temperatures ranging from 
33°C to 35.9°C (mild hypothermia) have a minimal effect 
on the enzymatic activity of coagulation factors; however, 
reduced platelet adhesion and aggregation are observed.7,8 
Temperatures below a threshold of 36.4°C and 34°C decrease 
the activation of glycoprotein IIb/IIa and P-selectin, respec-
tively, processes important for platelet adhesion.31 Because 
temperature is decreased below 33°C, into the moderate 
(32.9°C–28°) and severe (<27.9°C) hypothermic ranges, a 
further inhibitory effect on platelet activity is observed.7,8,32 
The inhibitory effect on platelets is coupled with a progres-
sive decrease in the enzymatic activity of coagulation fac-
tors, where at 25°C, enzyme activity ranges from 0% (FVIII 
and FIX) to 5% (FII and FVII).33
In this study, we report a progressive decrease in df and 
G′GP with a prolongation of TGP as temperature is reduced 
below 37°C (see Fig. 1). The progressive changes observed 
in df and TGP with hypothermia are indicative of a wors-
ening hypocoagulable state, producing df and TGP values 
more commonly associated with anticoagulated or diluted 
blood.14,16 However, the changes in df do not become sig-
nificant until a temperature of 32°C is reached, where df 
decreases from 1.73 ± 0.040 at 37°C to 1.67 ± 0.037 at 32°C 
(P = 0.0093). In contrast to standard coagulation testing, the 
gel point technique includes the vital contribution of plate-
lets and cellular components of coagulation. However, over 
the temperature range from 33°C to 35.9°C, the observed 
inhibitory effect of reduced temperature on platelet adhe-
sion does not seem sufficient to produce significant changes 
in the gel point parameters. When temperatures reach 
those synonymous with moderate hypothermia (<33°C), 
the additional inhibition of platelet and coagulation 
enzyme activity is likely to be the cause of this significant 
reductions in df. We observed a significant change in TGP 
only when the temperature decreases to 29°C (245 ± 44 at 
37°C to 391 ± 69 at 27°C, P = 0.0317), and no significant 
change was observed in G′GP (P > 0.75).
Hyperthermia is associated with hypercoagulability, 
where increases in temperature result in an increase in 
thrombin generation.9 The results of this study, however, 
show that increases in temperature >37°C and up to 43°C 
(temperatures synonymous with hyperthermia) had no sig-
nificant effect on df, G′GP, or TGP (Fig. 1). This finding sug-
gests that, in hyperthermic conditions, temperature alone 
does not significantly affect coagulation.
To better understand the changes we observed with 
df, we performed computational analysis that illustrate 
the nonlinear relationship between df and clot mass at the 
incipient clot stage of development. When temperature is 
reduced, a progressive decrease in df is observed, indicating 
a decrease in the complexity of the clot microstructure. This 
is illustrated in Figure 2, where a clot with df = 1.67 (33°C) 
has approximately 60% of the mass of a clot for which df 
= 1.73 (37°C). This value is reduced further at the lowest 
temperature investigated in this study (27°C), with a mean 
df of 1.62, where the clot would contain approximately 40% 
of the mass of a clot formed at 37°C. Small increases in df 
will result in an exponential increase in the mass of the 
clot network. A change in df from 1.73 to 1.80, for example, 
indicates an increase of 120% in the clot mass. The conse-
quences of increased clot mass are 2-fold. First, it will affect 
clot lysis, because there is an increase in polymerized fibrin 
that is more tightly packed. Second, more polymerized clot 
mass will result in increases in clot elasticity, which is sup-
ported by the significant positive correlation we observed 
between df and G′GP. This may be understood in terms of 
Figure 2. Computational simulation of fractal 
dimension df versus mass. A, Graph showing 
the relationship between the value of df of a par-
ticular structure and the mass incorporated into 
that structure. Substantial increases in mass 
are required to generate small increments of 
df. The mass value on the y-axis is normalized 
for the healthy index value of df (=1.73). B–D, 
Representations of different incipient microstruc-
tures that correspond to particular values of df 
are provided (cross = 1.65, circle = 1.73, and 
square = 1.80). The color of each node (unit 
sphere) within the fractal represents the local 
density of constituent nodes within a sphere of 
radii 5 units, and the color ranges from green (1 
neighboring node) to red (20 neighboring nodes).
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the viscoelasticity of cross-linked polymeric gel networks 
in which G′ is a function of polymer chain length between 
cross links. For idealized polymer systems with fixed cross 
links, increases in both G′ and df will result from an increased 
cross link density.34
The major limitation of the study was that gel point 
measurements at each of the different temperatures for 
each of the volunteers were not performed. The test is 
designed to be used in a near-patient setting, and it is 
performed with the use of whole nonanticoagulated 
blood. Hence, because of the limited numbers of AR-G2 
instruments available and to avoid multiple blood sam-
plings in each volunteer, not all 17 temperatures were 
studied in each subject. Thus, blood from different 
healthy volunteers was used at each temperature test-
ing condition. To limit any possible variations between 
the testing conditions, all participants were determined 
to have normal coagulation. The gel point measurements 
are taken at the initial or incipient stage of clot develop-
ment and are not measures of the mature clot. This has 
the advantage of providing a very rapid measure of the 
clotting properties. In addition, we have shown previ-
ously how the incipient clot acts as a template of mature 
clot growth28 and that df is significantly correlated with 
other viscoelastic measurements of the mature clot.16 
Regardless, this study highlights the potential of the gel 
point technique to measure the effects of temperature on 
coagulation. The gel point measurements have now been 
validated in the models of anticoagulation, dilution, and 
temperature.14,16 The results of this study suggest that 
preventing moderate-to-severe hypothermia (<32°C) and 
maintaining normothermia could be important for main-
taining normal clot microstructure formation. However, 
the changes in temperature >37°C (hyperthermic condi-
tions) do not seem to have such a pronounced effect on 
clot microstructure. Our results highlight the need for 
further clinical investigations, such as studying the role 
of temperature in critical illnesses such as sepsis and in 
patients with burn injury. E
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